Select Sidearea

Populate the sidearea with useful widgets. It’s simple to add images, categories, latest post, social media icon links, tag clouds, and more.

hello@youremail.com
+1234567890
SFA Therapeutics
THE ADVENT OF NEXT GENERATION DRUGS
TREATING AUTOIMMUNE, CHRONIC INFLAMMATORY DISEASE AND CANCER
Previous
Next

ABOUT SFA THERAPEUTICS

UNDERSTANDING THE COMPLEXITY OF THE IMMUNE SYSTEM

Our journey began with a deep fascination for the intricate world of the human gut bacterial ecosystem and its profound impact on overall well-being. Our founders, a team of passionate researchers and healthcare professionals, were intrigued by the pivotal role this complex microbiota plays in maintaining human health. The various bacteria produce a a complex, yet synergistic, set of compounds in our intestines that exhibit profound wide-ranging effects on metabolism and immune function.

 

THE DEEP DIVE

 

As we dove deeper into the science, we uncovered the potential of these biosynthetic molecules that mimic naturally occurring substances in addressing a variety of health challenges, from autoimmune disease to metabolic disorders. We were particularly captivated by how these simple organic compounds could influence complex cellular processes and serve as a communication bridge between our gut microbiome and immune system.

 

THE DISCOVERY

 

We discovered ways of increasing the selectivity and specificity of our biosynthetic compounds after elucidating pathways and targets. We have developed a platform technology that allows us to target specific diseases and create disease-specific drugs.

 

THE JOURNEY

Join us on this exciting journey as we work towards a healthier future, one molecule at a time.

 
 

 

Deriving drugs from bacterial metabolites found
in man means no genotoxicity, faster clinical development and safer treatments.

Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.

POWERFUL DRUGS

DERIVED FROM ENDOGENOUS SUBSTANCES 

PREDICTABLE OUTCOMES

Innovative Oral Formulations Allow for Consistent Clinical Outcomes

PATHWAY TARGETED

Small Molecules that Interact Selectively with Disease-specific Targets and Maintain Immune Homeostasis  

Small Molecules that Interact Selectively with Disease-specific Targets and Maintain Immune Homeostasis  

SUPERIOR SAFETY

Small Molecules that Mimic Endogenous Substances Found in the Human Body 

HIGHLY EFFICACIOUS

Boosts Anti-Inflammatory IL-10 Expression and Downregulates Pro-inflammatory Cytokines to Nomral Levels Preserving Positive Effects 

Portfolio

EXPLORE OUR SCIENCE

Our Latest News

Article by SFA Therapeutics Founders Featured in Drug Target Review

  In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches. The Promise…

SFA Therapeutics Strengthens Management Team with Appointment of Chief Medical Officer

JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ — SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory…

Ben Franklin Healthcare Investments: 1.3 Million in Four Companies

Ben Franklin Healthcare Investments Invests $1.3 Million in Four Companies   Ben Franklin Healthcare Investments continues support of SFA Therapeutics with…